Lilly to acquire Prevail for $22.50 per share in cash Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion).
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease.
Gene therapy is a promising approach with the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and dementia
The acquisition of Prevail will bring critical technology and highly skilled teams to complement our existing expertise at Lilly, as we build a new gene therapy program anchored by well-researched assets. We look forward to completing the proposed acquisition and working with Prevail to advance their groundbreaking work through clinical development."
finance.yahoo.com
Biotechs
BioCardia Anticipates DSMB Feedback on Interim Data1. BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial
BCDA today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal Phase 3 CardiAMP Heart Failure Trial that is currently enrolling nationwide for infusion of BioCardia’s CardiAMP™ autologous cell therapy to the myocardium. The DSMB is then anticipated to provide its written feedback approximately 24 hours later. BioCardia plans to provide an announcement pre-market on December 17 , 2020 summnarizing the feedback and outlining the next resulting steps.
The CardiAMP Heart Failure study has been approved by the FDA to enroll up to 260 patients at up to 40 centers. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy in the treatment of patients with ischemic heart failure . The FDA has said that the trial qualifies as a pivotal trial to produce the primary data to support market registration for the CardiAMP cell therapy for this significant unmet clinical need.
www.globenewswire.com
2. BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
today announced it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 16, 2020, subject to the satisfaction of customary closing conditions.
finance.yahoo.com
Arvinas Nearly Doubles on Promising Cancer Drug ResultsArvinas Nearly Doubles on Promising Cancer Drug Results
The test results show the Arvinas drugs' potential for treating breast and prostate cancer, Cantor said.
Arvinas (ARVN) - Get Report shares blasted off Monday as Cantor Fitzgerald offered bullish comments on the biopharmaceutical company after it reported positive news on its breast and prostate cancer treatments.
“For ARV-471, interim Phase 1 data show potential for best-in-class safety and tolerability, estrogen receptor (ER) degradation superior to that previously reported for the current standard of care agent (fulvestrant), and robust efficacy signals in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative (ER+/HER2-) breast cancer,” the company said in a statement.
The test results show ARV-471’s potential as the best-in-class potential estrogen receptor degrader, Cantor analyst Alethia Young wrote in a commentary cited by Bloomberg. The results are “very encouraging and demonstrated ARV-471 was active,” Young wrote. She has an overweight rating and a $66 price target on Arvinas.
“The efficacy signals include one Response Evaluation Criteria in Solid Tumors (RECIST) confirmed partial response (PR), two additional patients with unconfirmed PRs, and a clinical benefit rate (CBR) of 42%,” Young said.
Separately, Cantor said that “for ARV-110, the ongoing dose escalation portion of the Phase 1/2 trial in men with metastatic castration-resistant prostate cancer (mCRPC) has provided additional evidence of anti-tumor activity and patient benefit, including a prostate specific antigen reduction of more than 50% (PSA50) rate of 40% in a molecularly defined patient population.”
Further, “Arvinas has initiated a Phase 2 dose expansion to explore a two-pronged development strategy, including the potential for accelerated approval in molecularly defined, late-line patients, and broader development in less-heavily pretreated mCRPC patients with fewer androgen receptor (AR)-independent mechanisms of tumor resistance,” Young said.
Oppenheimer Upgrades Arvinas Inc. (ARVN) to Outperform, Following Clinical Update
www.thestreet.com
www.streetinsider.com
Solid Biosciences Announces $90 Million Private PlacementSolid Biosciences Announces $90 Million Private Placement
Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions.
The private placement includes new investors Suvretta Capital Management, LLC and Aspire Capital Fund, LLC and existing investors, including RA Capital Management, Perceptive Advisors, LLC, Bain Capital Life Sciences, EcoR1 Capital, LLC, Boxer Capital, and Ikarian Capital, LLC, as well as certain board members and executive officers.
In this private placement, the Company is selling 24,324,320 shares of common stock at a price of $3.70 per share.
The Company expects to use net proceeds from the private placement to fund research and development expenses, including the advancement of SGT-001, and for working capital and other general corporate purposes.
finance.yahoo.com
$BXRX can rise in the next daysContextual immersion trading strategy idea.
Baudax Bio is a pharmaceutical company, develops and commercializes products for hospitals and other acute care settings.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $4,34;
stop-loss — $4,23.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
#IMMU look at Risk vs. Reward #VolatilitywatchThis trade brings opportunity for investors looking for a a company with great fundamentals and nice risk/reward potential into end of year. As the chart shows (blue arrows) I am awaiting a buying opp around the blue trend line.
From current stock price, potential risk/reward around 3.5 : 1
downside risk: $1.39
upside reward: $3.50-$5
Recent selloff after earnings showed strong support at the $11.59 level, which also made a double bottom.
This selloff started around July, 2018. to emphasize the double bottom even more, the pullback from peak to trough retraced .618; a key level of Fibonacci support.
MACD indicator showing strong convergence with price
Price above 20 day moving average.
5-day exponential moving average above 20 day moving average, indicating strength in trend.
Conclusion: $IMMU seems to bring opportunistic risk/ reward to investors who are sidelined. Double bottoms are significant patterns when looking for price reversal.
Tip # 11: Some investors wait to buy until after stock price crosses above moving averages such as the 20, 50, 100, and 200 day. These are key phycological levels to watch when trading and investing.
Like and follow so I can continue giving trend analysis and trade ideas. Thank you in advance =)
Follow me on twitter or Instagram @Volatilitywatch
Disclosure: I do not own IMMU. This is not a note to buy or sell. Please do your homework before investing.
EYPT | Range bound Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out.
This marks potential accumulation range for anyone looking to build a position in EYPT.
Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down.
Range low/ highs, range from $1.42 - $1.87 is approximately $0.45 of profit both ways up (~20%+) until EYPT confirms they are adhering to terms of loan with CRG.
Weekly MACD and Stochastics have divergence with stock price. This could infer spring board type action on good news (break below range could cause problems).
Previous quarter showed that $EYPT was on track w/ meeting terms of CRG loan agreement.
positive earning/ ER beat should help satisfy some hedge funds/ big $ investors. I remain cautiously optimistic.
$EYPT could potentially come and test lows of the range within next week. I am looking to use this as a way to add to current position/ swing trade it to highs and lower cost basis on my long-position.
**On the other hand, falling below this range could cause knee jerk reaction/ selloff. I am going to be watching this carefully.
Tip # 7: When trading, It is very important to have a game plan. It is good practice to establish rules to your system (i.e. do you buy in increments?, at what point do you not like the investment anymore? how long are you willing to hold?).
- Please Like and Follow for trade ideas & so I can continue to chart and build my reputation. Thank you in advance =)
Have a Twitter? check out my page for more: @volatilitywatch
Disclosure: I am long EYPT. This is not a note to buy or sell. Please do your homework before investing.
//-----------------------------------------------------------------------------------
Check out current trade in TGTX =) #BULLISH
Galapagos Has Peaked, Nowhere To Go But DownGalapagos announced today a large investment and a 10-year deal with Gilead $GILD. The stock gapped due to Gilead buying 10% of Galapagos at $158/share. However, when stocks gap up on investments at a premium price, they almost always fall (see $MGI, $ARWR)
An analyst at Raymond James agrees, saying he believes $GLPG stock has now fully realized his price target by achieving his core investment thesis.
As terms of the deal, $GILD has promised not to increase their stake in Galapagos for another 10 years, so a buyout is off the table
Cala #VolatilityWatchAfter a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Cala looks to have established a double bottom. New strong uptrend suggests it has potentially capitulated from the selloff making these levels very attractive for any investors who are sidelined and looking for a good technical/ fundamental trade in biotech. Cala looks to be in the midst of a new uptrend.
June 2019 selloff marked double bottom for CALA.
This looks to be very attractive from risk vs reward standpoint (Assuming markets stay strong, I see approximately $0.40 downside vs $1.50 upside).
Extrapolating previous price patterns (shown in chart) Cala looks to be in the midst of 2nd wave (Bullish corrective wave).
the projection is based off previous price patterns where CALA retraced approximately .618 and extended above the 1.618 Fibonacci extension level.
trend indicators also signaling uptrend in play (see chart).
Tip # 9: Stop losses are a good way to get you out of a trade that you don't want to be in. But remember, they only work during market hours.
Please Like and Follow so I can continue giving trade ideas and build up my reputation. Thank you in advance =)
Have a Instagram or Twitter? follow me @VolatilityWatch
Disclosure : I do not own a position in Cala. I may buy/ sell within the next 72 hours. This is not a note to buy or sell. Please do your own homework before investing.
BLUEBIRD BIO INC - AWESOME TIME TO LONG THIS STORYAnother pharma company - with amazing correct Elliot 5 waves which you can try to ride.
1. Buy 131.32
2. Take profit: 213
3. SL: 115.90
RISK/REWARD: 5.38, potential profit 62.39%
Neovacs - strong bullish trend expectedResults of IFN Kinoide on Lupus research are very significant (95% efficacy observed). Volume increase strongly on the biotech and strong breakout of the 0.25 resistance has been observed. Pullback on the 0.25 level is resolved and the stock is now in perfect conditions for a bullish rally. First target is 0.5
I am a permabear... but how can you ignore all this confluence? Target 10,000. I can't believe I said that... but there is just too much confluence to ignore this possibility. However, a breakdown from this wedge will likely eliminate this play. Either we hit it fast in 2019, or this long is off the table. Let me know your thoughts.
NASDAQ: $QURE looks like it's about to SHIT THE BED! #StayAwayNASDAQ: $QURE looks like it's about to SHIT THE BED! #StayAway ...or consider SHORT'ing if shares are available from your Broker! Looks like an EASY WIN!
$NANO.OL Breakout watch Nordic Nanovector 177Lu biotechNordic Nanovector $NANO.OL pushing above NOK68 resistance on significant volume, closing at strong 70.3 before weekend. This indicates another attempt at breaking out of long time downtrend that has been effect since ATH back in december 2016.
Investors are seemingly very satisified with recent Q3 report and #ASH18 abstracts presented by CEO Eduardo Bravo and his team.
Nordic Nanovector Q3 2018 and ASH 2018 abstract presentation transcript
nanoinvestors.wordpress.com
Novartis higlights 177Lu isotope for use in oncology radiopharmaceuticals
nanoinvestors.wordpress.com
Betalutin FDA Fast Track Status
nanoinvestors.wordpress.com
Betalutin Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma.
nanoinvestors.wordpress.com
Nordic Nanovector Comprehensive Company Presentation Updated October 2018
nanoinvestors.wordpress.com
Nordic Nanovector mentioned by analyst ABG Sundal Collier as likely object of M&A interest
nanoinvestors.wordpress.com
Nordic Nanovector Analyst Coverage
nanoinvestors.wordpress.com
Omeros looks set to attempt new nove upwards on the back of $IBBOmeros has been consolidating after breaking out of its long downtrend, but looks set to make a new attempt to move upwards, coinciding with a strong move in the $BB etf.
Needs volume of trade to confirm this move, while investors are waiting for a list of catalysts to trigger interest.
Small Pharma Big Backers and Partners - LONG SNG (Synairgen)Prudent Drug Discovery Company
Low market cap ( appox £13m at time of writing ).
Issues shares very rarely ( last placing nearly four years ago ).
Has material interest in its work from larger partners ( Pharmaxis ).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest across all fibrotic indications at circa 17% of all partnering proceeds.
Potential of drug appears across multiple uses now ( not just lung-related ) and indications from Pharmaxis looking very good.
Recent interviews from Pharmaxis management suggest a good chance of a deal with major pharma in H2.
Low free float in the stock ( 60% in hands of major shareholders ).
Major funds holding ( Woodford Investment Management and Lansdowne Partners ).
High profile investors holding stakes ( Richard Griffiths and Leonard Licht ).
These high profile investors have been raising, rather than reducing their stakes in the company, periodically.
For a risky smallcap biotech stock it appears well placed to survive and thrive, regardless of the short term success of a sale/licencing deal of LOXL2 by Pharmaxis, making it considerably less risky than most biotech stocks in the long term. However, the indications and noises being made about LOXL2 by Pharmaxis are looking as positive as you could hope for, and backed up by them putting their money where their mouth is in the first place and increasing their stake for cash.
LABU next wave of momentum coming Labu beginning of september had a nice break of prior highs. we have spent the last couple weeks consolidating over that recent high
XBI: Biotech slide back to channel bottom until End-JulyXBI, LABU, BIB should slide to the bottom of the channel until End-July. See high moving-average divergence, reconvergence and channel pattern. Short unless something changes.
APOP - Strong Momentum, Strong TrendThe lower trend line has been very consistent on this stock, and until it breaks, this thing is a winner.
Low float, high short interest, potential for huge gains. NASDAQ:APOP
